Women’s healthcare company TherapeuticsMD Inc (NASDAQ:TXMD) is one of the companies to have come on to the radars of many investors in recent days.
Over the course of the past week, the TherapeuticsMD stock has managed to clock gains of as much as 7% and in this situation; it might be a good idea to take a look at an announcement from the company on October 15. On that day, TherapeuticsMD announced that it appointed a new Chief Business Officer in the form of Mark Glickman. It is a key position and one that could have a profound effect on the company’s business in the near future.
Glickman is a seasoned professional in the pharmaceuticals industry and had previously serves as the Chief Commercial Officer in companies like Aralez Pharmaceuticals and Esperion. On the other hand, he had also served as the Executive Vice President of Sales and Marketing at Auxilium Pharmaceuticals.
It seems that the appointment has come as a source of optimism for many investors and it is going to be interesting to see if the TherapeuticsMD stock can continue to hold on to this momentum in the coming days. Investors could do well to keep an eye on the news with regards to TherapeuticsMD in the coming days.
